Multiple Sclerosis Research Repository

“Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic”: Jerome de Seze et al

  1. “Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic”: Jerome de Seze et al
  1. Rituximab in RRMS: RIFUND-MS trial: no significant difference was observed between the groups (rituximab and tecfidera) for the EDSS, even though rituximab outperformed tecfidera in terms of reducing relapses/ARR, no new MRI activity, and reduced numbers of T2 and GD+ lesions
  2. Ocrevus, Phase II trials (OPERA I and OPERA II): results were inconclusive due to a failure of the statistical hierarchical testing procedure; in the OLE, patients switching from IFN-B-1a to Ocrevus (at 2 years) had a similar ARR at 5 years; the proportion of patients withCDP at five years was lower with Ocrevus compared to patients switching from IFN-B-1a to Ocrevus (16.1% to 21.3%, respectively); brain volume loss was unchanged in patients treated with Ocrevus for 5 years
  3. Kesimpta in RMS: ASCLEPIOS I and ASCLEPIOS II: annualized rate of brain volume loss did not differ significantly between patients treated with Kesimpta vs Aubagio, even though Kesimpta outperformed Aubagio in terms of T1 GD+ lesions; in ASCLEPIOS I, patients on Kesimpta had a lower adjusted ARR than those in the Aubagio group (similar results seen in ASCLEPIOS II)
  4. Briumvi in RMS:
  5. ULTIMATE II trial: 43% of Briumvi group showed NEDA vs 11.4% in Aubagio group; however, no significant difference in the worsening of disability at 12 weeks was found between Briumvi and Aubagio patients in the pooled analysis of the 2 trials (5.2% vs 5.9%); brain volume change was not significant between the 2 groups

Published by

kaylin bower

Leave a comment